Crossmark Global Holdings Inc. Acquires 23,719 Shares of Gilead Sciences, Inc. $GILD

Crossmark Global Holdings Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 551,922 shares of the biopharmaceutical company’s stock after acquiring an additional 23,719 shares during the period. Gilead Sciences makes up 1.0% of Crossmark Global Holdings Inc.’s portfolio, making the stock its 14th largest holding. Crossmark Global Holdings Inc.’s holdings in Gilead Sciences were worth $67,743,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in GILD. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences in the third quarter worth approximately $26,000. Ares Financial Consulting LLC bought a new position in Gilead Sciences during the fourth quarter valued at approximately $28,000. Financial Consulate Inc. boosted its holdings in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. boosted its holdings in Gilead Sciences by 54.8% in the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares during the last quarter. Finally, MTM Investment Management LLC grew its position in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of a number of research reports. Citigroup boosted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Royal Bank Of Canada dropped their price target on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating on the stock in a research note on Friday. Wolfe Research lifted their price objective on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective for the company. Finally, Daiwa Securities Group raised their target price on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $157.50.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. This represents a 1.76% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 63,000 shares of company stock valued at $9,238,250. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Down 2.0%

Shares of Gilead Sciences stock opened at $131.33 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company has a market capitalization of $163.01 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.77 and a beta of 0.31. The company has a fifty day moving average of $139.59 and a 200 day moving average of $132.87.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 49.45% and a net margin of 30.99%.The business’s revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s payout ratio is currently 48.45%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Truist Financial reaffirmed its buy rating on Gilead and raised its price target to $157 from $155, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Gilead reported Q1 EPS of $2.03 and revenue of $6.96 billion, both ahead of analyst expectations, supported by HIV and Trodelvy sales growth. Yahoo Finance
• Positive Sentiment: The company raised its Yeztugo 2026 sales guidance to $1 billion from $800 million, signaling stronger-than-expected launch momentum. Yahoo Finance
• Neutral Sentiment: RBC slightly reduced its price target to $122 from $123 and kept a sector perform view, suggesting a more cautious stance but no major change in thesis. Benzinga
• Negative Sentiment: Gilead cut its 2026 EPS guidance to a loss range of -$1.05 to -$0.65, a major deterioration from prior profit expectations, due to acquisition charges and financing costs. Reuters
• Negative Sentiment: Investors also appear concerned that near-term growth is being driven more by older products like Descovy and Biktarvy than by the much-anticipated Yeztugo launch, creating questions about the pace of future growth. Yahoo Finance

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.